Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292


Real-time Estimate Quote. Real-time Estimate CHI-X - 01/25 09:50:43 am
7889 GBX   +1.44%
09:34aTHE LATEST : German state sees chaotic over-80s vaccine start
09:27aStock Futures Diverge Amid Renewed Tech Surge
07:49aASTRAZENECA : Says Leukemia Drug Calquence Met Endpoints in Trial
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Australia orders more COVID-19 vaccines for total of 135 million doses

11/05/2020 | 12:36am EST
FILE PHOTO: Vials and medical syringe are seen in front of Novavax logo in this illustration

SYDNEY (Reuters) - The Australian government has agreed to purchase two more COVID-19 vaccines in development, beefing up the country's prospective arsenal against the pandemic to 135 million doses as it aims to complete a mass inoculation programme within months.

Prime Minister Scott Morrison said on Thursday the government will buy 40 million vaccine doses from Novavax, and 10 million from Pfizer and BioNTech.

That adds to the 85 million doses Australia has already committed to buy from AstraZeneca and CSL Ltd should trials prove successful, taking the country's total anticipated outlay to A$3.2 billion ($2.3 billion).

"We aren't putting all our eggs in one basket," Morrison told reporters in Sydney.

Health Minister Greg Hunt said the Novavax and Pfizer-BioNTech vaccines, which will be manufacturd in the United States and Europe, would complement the AstraZeneca and CSL products, which would be manufactured in Australia.

"That means we are now in a very strong position with the portfolio of four different vaccines, two protein, one viral vector and one MRMA, which is the Pfizer vaccine, and that's innovative - the world hasn't had an MRMA vaccine before," Hunt told TV broadcaster Nine Network.

The Pfizer-BioNTech, AstraZeneca and Novavax vaccines are considered to be among the leading candidates in the global race to receive regulatory approval.

Should trials prove successful, Australia expects to receive the first batches of the AstraZeneca vaccine in early 2021 and begin a mass rollout in March to be completed by the end of the year.

If all four vaccines come to market, Australia and its population of 26 million people will find itself with excess doses, even allowing for the fact that many of the candidates in development require two doses to be effective.

Australia has said it plans to donate any excess doses to Pacific Island countries and has committed to spending around A$525 million to ensure Pacific nations and East Timor achieve full immunisation coverage.

Australia is the largest aid donor to the Pacific islands and has sought in recent months to step up its engagement out of concern it risks being overshadowed by Chinese aid and financial support.


The announcement of the new planned vaccine purchases came as Australia recorded no cases of locally transmitted COVID-19 over the past 24 hours for the second time in a week. The country on Sunday recorded the first day without any local cases since early June.

Australia has reported just over 27,600 coronavirus cases and 907 deaths, far fewer than most other developed countries thanks to extensive testing, contact tracing and lockdowns.

As national case numbers have slowed slowed to fewer than 10 each day, states and territories have been reopening borders and relaxing differing levels of social distancing restrictions.

Qantas Airways on Thursday said it would boost the number of flights between between New South Wales and Victoria states after officials announced on Wednesday that border restrictions would be lifted later this month.

The national carrier will go from the ten return flights it is currently operating each week between Sydney and Melbourne to more than 250 flights between the two states weekly. The Sydney-Melbourne route was one of the busiest in the world before the pandemic.

($1 = 1.3916 Australian dollars)

(Reporting by Renju Jose; Editing by Aurora Ellis, Stephen Coates and Jane Wardell)

By Renju Jose and Colin Packham

© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 1.44% 7856 Delayed Quote.6.19%
BIONTECH SE 1.45% 110.4278 Delayed Quote.33.02%
CSL LIMITED 2.17% 274.6 End-of-day quote.-3.03%
NOVAVAX, INC. 2.64% 129.7 Delayed Quote.13.87%
NUFARM LIMITED -0.21% 4.74 End-of-day quote.15.61%
PFIZER INC. -0.45% 36.36 Delayed Quote.-0.71%
QANTAS AIRWAYS LIMITED 0.00% 4.85 End-of-day quote.0.00%
All news about ASTRAZENECA PLC
09:34aTHE LATEST : German state sees chaotic over-80s vaccine start
09:27aStock Futures Diverge Amid Renewed Tech Surge
07:49aASTRAZENECA : Says Leukemia Drug Calquence Met Endpoints in Trial
07:29aMerck ends COVID vaccine program, cites inferior immune responses
07:23aEU to require advance registration of COVID-19 vaccine exports
06:59aMerck Scraps Covid-19 Vaccine Candidates
06:57aBioNTech-Pfizer COVID-19 Shot Gains Australian Approval
06:49aAstraZeneca's COVID-19 Vaccine Gains Approval in Bahrain
06:45aMerck ends COVID vaccine program, cites inferior immune responses
06:43aMARKET CHATTER : EU to Meet With AstraZeneca to Seek Clarification on COVID-19 V..
More news
Financials (USD)
Sales 2020 26 404 M - -
Net income 2020 2 955 M - -
Net Debt 2020 13 238 M - -
P/E ratio 2020 42,5x
Yield 2020 2,65%
Capitalization 140 B 139 B -
EV / Sales 2020 5,79x
EV / Sales 2021 4,98x
Nbr of Employees 70 600
Free-Float 95,7%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 25
Average target price 126,47 $
Last Close Price 106,39 $
Spread / Highest target 46,7%
Spread / Average Target 18,9%
Spread / Lowest Target -15,2%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON3.92%430 552
ROCHE HOLDING AG3.06%308 615
NOVARTIS AG2.73%220 726
MERCK & CO., INC.-1.00%204 882
PFIZER INC.-0.71%203 159